Cantor Fitzgerald Reiterates Overweight on Disc Medicine, Maintains $85 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Kristen Kluska has reiterated an Overweight rating on Disc Medicine (NASDAQ: IRON) and maintained a price target of $85.
December 20, 2023 | 3:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald analyst Kristen Kluska reiterated an Overweight rating on Disc Medicine and maintained a price target of $85.
The reiteration of an Overweight rating and the maintenance of a high price target by a reputable analyst like Kristen Kluska could lead to increased investor confidence in Disc Medicine, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100